IMV Inc. – NASDAQ:IMV

Add to watchlist

$0.731

+0.61

+508.49%

Market closed

Open in about 7 hours

-84.21%

month

-84.81%

quarter

-87.95%

year

Market Cap	9.63M
Enterprise value	444.17M

P/E	-0.12
EV/Sales	N/A
EV/EBITDA	-12.37
Price/Sales	N/A
Price/Book	-66.11
PEG ratio	N/A
EPS	-3.42

Revenue	N/A
EBITDA	-37.46M
Income	-36.61M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

IMV Inc. (NASDAQ:IMV): Profit margin
Mar 2022	0	-10.82M
Jun 2022	0	-9.76M
Sep 2022	0	-7.43M
Dec 2022	0	-8.59M

IMV Inc. (NASDAQ:IMV): Debt to assets
Mar 2022	40833000	29.13M	71.35%
Jun 2022	40493000	38.07M	94.04%
Sep 2022	32272000	38.58M	119.57%
Dec 2022	31348000	37.95M	121.06%

IMV Inc. (NASDAQ:IMV): Cash Flow
Mar 2022	-9.96M	-32K	-42K
Jun 2022	-6.92M	-604K	9.96M
Sep 2022	-10.21M	-231K	1.49M
Dec 2022	-6.30M	-207K	5.98M

IMV alternative data

IMV Inc. (NASDAQ:IMV): Employee count
Aug 2023	63
Sep 2023	63
Oct 2023	63
Nov 2023	63
Dec 2023	63
Jan 2024	63
Feb 2024	63
Mar 2024	63
Apr 2024	63
May 2024	63
Jun 2024	63
Jul 2024	63

IMV
Hedge Funds Holdings Q1 2023

6.19% -93.81%

of IMV is owned by hedge funds

10 -8

hedge funds hold IMV stock

516.36K -1.13M

shares is hold by hedge funds

IMV hedge funds holdings changes

Quarter	Transcript
Q4 2022 16 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 12 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 11 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 13 May 2022	Q1 2022 Earnings Call Transcript

IMV
Executives

Insider	Age	Since	Compensation
Mr. Pierre Labbe C.A., C.P.A., CA, CPA, ICD (1965) Chief Financial Officer	60		$419,420

IMV
Latest News

Wednesday, 21 February 2024
13:54	BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.	prnewswire.com
Monday, 12 February 2024
14:17	BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.	prnewswire.com
Wednesday, 26 July 2023
07:05	IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process	businesswire.com
Monday, 8 May 2023
16:30	IMV Receives NASDAQ Delisting Notice	businesswire.com
Tuesday, 2 May 2023
16:15	Horizon Technology Finance Announces First Quarter 2023 Financial Results	prnewswire.com
Monday, 1 May 2023
12:30	IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives	businesswire.com
Friday, 31 March 2023
16:15	IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	businesswire.com
Monday, 27 March 2023
16:15	IMV Inc. Announces Changes to Its Board of Directors	businesswire.com
Thursday, 16 March 2023
11:02	IMV Inc. (IMV) Q4 2022 Earnings Call Transcript	Seeking Alpha
Thursday, 9 March 2023
07:05	IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023	Business Wire
Saturday, 12 November 2022
09:25	IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript	Seeking Alpha
Tuesday, 8 November 2022
07:05	IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022	Business Wire
Thursday, 1 September 2022
07:05	IMV Inc. to Present at Two Investor Conferences in September	Business Wire
Thursday, 11 August 2022
14:17	IMV Inc. (IMV) CEO Andrew Hall on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 4 August 2022
07:05	IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022	Business Wire
Tuesday, 17 May 2022
08:05	IMV Inc. to Present at the H.C. Wainwright Global Investment Conference	Business Wire
Friday, 13 May 2022
12:13	IMV Inc. (IMV) CEO Andrew Hall on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 6 May 2022
07:05	IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022	Business Wire
Wednesday, 6 April 2022
07:05	IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting	Business Wire
Monday, 4 April 2022
07:05	IMV Inc. to Present at Two Upcoming Investor Conferences	Business Wire
Thursday, 17 March 2022
14:34	IMV Inc. (IMV) CEO Andrew Hall on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 10 March 2022
07:05	IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022	Business Wire
Thursday, 17 February 2022
07:05	IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform	Business Wire
Thursday, 13 January 2022
10:46	IMV Doses First Patient in the Mid-Stage Study With Keytruda	Zacks Investment Research
Wednesday, 5 January 2022
07:05	IMV Inc. to Present at Two Upcoming Investor Events	Business Wire
Tuesday, 23 November 2021
08:05	IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference	Business Wire
Thursday, 11 November 2021
13:49	IMV Inc. (IMV) CEO Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 4 November 2021
07:05	IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021	Business Wire
Thursday, 7 October 2021
09:05	Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics	Business Wire
Friday, 1 October 2021
08:05	Potential Response Predictors to IMV's Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting	Business Wire

Ideas & Opinions

Seeking Alpha 8 Apr 2021

Merck & Co. Is Flatlined But Watch For Its Revival

Frequently Asked Questions (FAQ)

What's the price of IMV stock today?

One share of IMV stock can currently be purchased for approximately $0.73.
When is IMV's next earnings date?

Unfortunately, IMV's (IMV) next earnings date is currently unknown.
Does IMV pay dividends?

No, IMV does not pay dividends.
How much money does IMV make?

IMV has a market capitalization of 9.63M.
What is IMV's stock symbol?

IMV Inc. is traded on the NASDAQ under the ticker symbol "IMV".
What is IMV's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of IMV?

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are IMV's key executives?
IMV's management team includes the following people:
- Mr. Pierre Labbe C.A., C.P.A., CA, CPA, ICD Chief Financial Officer(age: 60, pay: $419,420)
How many employees does IMV have?

As Jul 2024, IMV employs 63 workers.
When IMV went public?

IMV Inc. is publicly traded company for more then 17 years since IPO on 24 Oct 2007.
What is IMV's official website?

The official website for IMV is imv-inc.com.
Where are IMV's headquarters?

IMV is headquartered at 130 Eileen Stubbs Avenue, Dartmouth, NS.
How can i contact IMV?

IMV's mailing address is 130 Eileen Stubbs Avenue, Dartmouth, NS and company can be reached via phone at +1 902 492 1819.

IMV Inc.

imv-inc.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

+1 902 492 1819

130 Eileen Stubbs Avenue
Dartmouth, NS B3B 2C4

CIK: 0001734768
ISIN: CA44974L1031
CUSIP: 44974L103